You are here

New Formulation of Brimonidine Tartrate Receives Approval

IRVINE, Calif., Aug 19, 2005 (BUSINESS WIRE) -- Allergan, Inc. (NYSE:AGN) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market Alphagan P (brimonidine tartrate ophthalmic solution) 0.1%, indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

The new product is an optimized formulation of ALPHAGAN(R) (brimonidine tartrate ophthalmic solution) 0.2%, and was developed to further minimize drug exposure while maintaining the drug's favorable efficacy profile. This FDA approval is the latest advance in the Alphagan Franchise, which includes Alphagan P 0.15%, and currently reflects the third-largest selling glaucoma franchise in the world(1).

"Our goal in developing Alphagan P 0.1% has been to ensure maximal efficacy of brimonidine with the least drug exposure possible," said Dr. Scott Whitcup, Allergan's Executive Vice President, Research & Development. "By improving bioavailability compared to the original Alphagan P 0.2%, we have managed to decrease drug concentration by half without sacrificing efficacy. This milestone underscores Allergan's commitment to providing eye care specialists and patients with safe and efficacious medicines."

In a clinical trial, Alphagan P P ophthalmic solution 0.1% was proven to have IOP-lowering efficacy equivalent to Alphagan P 0.2%, effectively lowering IOP in patients with open-angle glaucoma or ocular hypertension by approximately 2-6 mmHg. Alphagan P P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. The most frequently reported adverse events included allergic conjunctivitis, conjunctival hyperemia and eye pruritus. Full prescribing information for Alphagan P P 0.1% can be found at

Source: Allergan, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs